$EMBC

Morris Milton Mayo sold $37K of EMBC

Morris Milton Mayo sold 6,293 shares of Embecta Corp. (EMBC) at $5.88 on 2026-09-04.

Original reporting
SEC EDGAR · Morris Milton Mayo
Published Sep 8, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EMBC
Neutral
high confidence
Mentioned
$EMBC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EMBCNeutralLow
01

Why it matters

Minor insider sell with limited market relevance.

02

Market read

Low relevance; no actionable trading signal.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$EMBCNeutralHigh confidence
Context

Director Morris Milton Mayo sold 6,293 shares for $36,971, reducing his stake to 53,828 shares.

Expected impact

No material price movement expected.

Evidence & confidence

The sale amount is small relative to float and typical insider activity; market impact is limited.

Market effects

None significant for the medical device sector.

No regional effect.

Limited to EMBC shareholders.

Counterpoint

The sale could be routine liquidity need, not a negative signal.

Key entities

  • Embecta Corp.

    Medical device manufacturer listed on Nasdaq.

  • Morris Milton Mayo

    Director of Embecta Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EMBCMedAI 8/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (NASDAQ:EMBC) held its FY2026 Q3 earnings call. Revenue was $271.7M, down 8.1% YoY, with U.S. revenue down 24.6% and international up 11.5% on Owen Mumford strength. Adjusted EPS was $0.56. Free cash flow was $41M. FY2026 guidance: revenue $1.015B-$1.035B, adjusted EPS $1.80-$1.90, margin 23.5%-24%.

$EMBCHighAI 9/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (EMBC) reported Q3 FY2026 revenue of $271.7 million, down 8.1% YoY, with U.S. revenue down 24.6% and international revenue up 11.5%. Adjusted EPS was $0.56. The company raised FY2026 adjusted operating margin guidance to 23.5% to 24% and EPS to $1.80 to $1.90, reaffirming revenue guidance of $1.015B to $1.035B.

$EMBCMed

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

Embecta Corp. (EMBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Aug 7, 2026 (GLOBE NEWSWIRE) – Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and n

$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).